Abstract: Tumor necrosis factor inhibitors (TNFi) have established efficacy in psoriasis and psoriatic arthritis; however, there are concerns regarding the risk of lymphoma with their use. Although current data suggest that this risk is not increased with TNFi treatment, there are no data on the risk of recurrence of previously treated lymphoma under TNFi therapy. Herein, we describe a 46-year-old man with recurrent non–Hodgkin lymphoma whose refractory psoriatic arthritis was effectively treated for 5.5 years with the TNFi etanercept, initiated just 7 months after achieving lymphoma remission, without recurrence of non–Hodgkin lymphoma. However, he subsequently died 6.5 years later of pancreatic adenocarcinoma.
From the *Department of Medicine, Englewood Hospital and Medical Center, Englewood; and †Institute for Rheumatic and Autoimmune Diseases, Overlook Medical Center, Summit, NJ.
The authors declare no conflict of interest.
Correspondence: Neil Kramer, MD, FACP, FACR, Institute for Rheumatic and Autoimmune Diseases, Overlook Medical Center, 33 Overlook Rd, Suite 211, Summit, NJ 07901. E-mail: firstname.lastname@example.org.